Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus KEFLEX.
ARBLI vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
10 mg orally once daily.
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic